A complete application in a minute
Tailored resume and cover letter, ready to send.
St. Anna CCRI in Vienna seeks a postdoctoral researcher to join one of six groups within the FWF Emerging Fields Consortium, studying ribosome biology and translational control in pediatric cancer biology and therapy resistance.
The role combines genomic, proteomic, biochemical and structural approaches to decode translation regulation and identify novel therapeutic vulnerabilities in solid and hematological pediatric cancers, contributing to safer treatments for children and adolescents.
Our FWF Emerging Fields Consortium brings together six complementary research groups across leading biomedical research institutions in Vienna to investigate ribosome biology and translational control as a new and largely unexplored layer of pediatric cancer biology and therapy resistance.
By combining cutting-edge genomic, proteomic, biochemical and structural approaches, we aim to decode cancer-specific mechanisms of translational regulation, the \"ribosome code\", and identify novel therapeutic vulnerabilities that could contribute to safer and more effective treatments for children and adolescents with solid and hematological cancers.
As a postdoctoral researcher, you will join one of the participating research groups while being part of a multidisciplinary consortium bringing together complementary expertise in pediatric cancer, translational regulation, RNA biology, functional genomics, proteomics and structural biology.
Find more information here: Emerging Fields - FWF
Research focus: Mechanisms of translational regulation during cellular stress.
The Karagöz lab combines quantitative biochemistry with genome-wide approaches, including CLIP-seq, RNA-seq and Ribo-seq, to dissect mechanisms of translational regulation.
The postdoctoral researcher will map the translational landscape in pediatric cancer models using high-resolution Ribo-seq and investigate the underlying molecular mechanisms through unbiased genetic screens
Research focus: Fusion driven pediatric sarcomas.
The Tomazou lab investigates the biology of fusion-driven pediatric sarcomas and has contributed novel concepts to the understanding of Ewing sarcoma. The group combines sequencing and STED super-resolution microscopy with pediatric sarcoma models, including patient material.
Jason Sims, Staff Scientist in the Tomazou group, contributes additional expertise in Nanopore sequencing, ribosomal DNA structure and transcriptional control, and ribosomal RNA variants.
Research focus: Mechanistic aspects of RNA metabolism.
The Falk lab investigates nuclear RNA degradation and pre-rRNA processing by the RNA exosome. The group combines biochemical reconstitution with structural analysis of macromolecular machines, including cryo-EM and structural modelling, to investigate ribosome biogenesis intermediates and mature cytoplasmic ribosomes.
Research focus: Molecular mechanisms of pediatric cancer oncoproteins.
The postdoctoral project will investigate how changes in translation and translation-associated processes affect cancer cell responses to drug treatment and the development of drug resistance, with the aim of identifying novel therapeutic strategies.
The Grebien lab brings expertise in molecular mechanisms of leukemia, acute protein degradation, CRISPR screening, affinity purification coupled to mass spectrometry, super-resolution microscopy and live-cell imaging.
Research focus: Systems biology, proteomics and functional genomics.
The Hein lab develops mass spectrometry-based proteomics approaches to quantitatively characterize the composition and dynamics of subcellular compartments and investigate proteome remodelling upon perturbation. The group also combines CRISPR-based genetic perturbations with single-cell transcriptomics for high-throughput functional validation of screening hits.
Research focus: Chromatin biology, epigenetics and leukemia.
The Seruggia lab uses multiple CRISPR screening approaches - including conventional knockout, base editing and prime editing - to investigate epigenetic determinants of leukemia. The group combines expertise in chromatin biology and epigenetics, functional genomics, hematology and mouse models of leukemia.
What you bring for this position:
Employment conditions, benefits and institutional services may vary depending on the host institution and will be communicated transparently during the respective recruitment process.
We are looking forward to your application! Applications should contain a one-page research statement outlining your scientific interests, how they connect to the aims of the Emerging Fields Consortium, and the research questions you would be particularly interested in pursuing.
Furthermore, it should include the following documents:
The application deadline is the 15.11.2026.
Applications are collected centrally on behalf of the participating research groups to provide candidates with one straightforward application process. Following the central application stage, recruitment and selection will be conducted by the respective host institution in accordance with its applicable recruitment procedures and policies. Candidates will be considered for the research groups indicated in their application.
We are committed to an inclusive and equitable recruitment process and welcome applications from qualified candidates regardless of gender, gender identity, sexual orientation, age, disability, ethnicity, religion or belief, or other personal characteristics.